Milestone Scientific Inc. (MLSS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.32 (-0.54% 1D, market cap $28.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, MLSS ranks #536 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (40/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, HSCS (HeartSciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and LFWD (Lifeward Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).
Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Macro rate sensitivity & RSI-14 (40.8) create a -16 pt regime headwind
While MLSS currently carries a cautious 40/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.39) and Max Pain ($0.34) forces dealer call-delta covering toward $0.61.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Milestone Scientific Inc. (MLSS) slipped -0.54% to $0.32, trading at 28% of its 52-week range ($0.22 – $0.58). Stretched risk/reward at 5x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.
Company Reports 500+ U.S. Leads, Expanding Healthcare Network Relationships, Federal Market Access, International Distribution and 300+ Issued and Pending Patents Worldwide Just 2% Penetration of Estimated U.S. Epidural
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MLSS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MLSS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Milestone Scientific Inc. (MLSS) ranks #536 by composite RQD confidence (40/100, grade D-) and #809 by equity capitalization ($28.6M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while MLSS leads on capital efficiency and profitability with -35.0% ROIC and 71.4% gross margin. MLSS currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MLSS
ACTIVE
Milestone Scientific Inc. | D- | 40/100 | 5.0x | 71.4% | -35.0% | -0.54% | $28.6M | Benchmark Subject |
| HSCS HeartSciences Inc. | D- | 39/100 | — | 59.1% | -35.0% | +7.12% | $17.5M | /hscs-vs-mlss → |
| LFWD Lifeward Ltd. | E | 31/100 | — | 96.0% | -35.0% | +2.78% | $16.7M | /lfwd-vs-mlss → |
| COCH Envoy Medical Inc. (Class A) | D- | 35/100 | — | -30.0% | -35.0% | -2.40% | $50.3M | /coch-vs-mlss → |
| MYO Myomo Inc. | E | 33/100 | — | 65.7% | -35.0% | +3.18% | $51.5M | /myo-vs-mlss → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported GAAP revenue of $9.0M (+4.0% vs. FY2024 revenue of $8.6M ) , GAAP net income of $5.7M, operating cash flow of -$2.9M, and free cash flow of -$2.9M (-0.1% YoY). On the balance sheet, MLSS closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.0M | $5.7M | -$2.9M | -$2.9M | $7.8M | — |
| FY2024 (FY) | 2024-12-31 | $8.6M | $4.7M | -$2.9M | -$2.9M | $9.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $6.9M | -$5.3M | -$5.3M | — | — |
As of 2026-11-02, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.32 (-0.54% 1D, market cap $28.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, MLSS ranks #536 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (40/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, HSCS (HeartSciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and LFWD (Lifeward Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).
Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MLSS last traded at $0.32 (-0.54% on volume of 263,513 shares), positioning the stock -17.95% below its 50-day simple moving average ($0.39) and -8.57% below its 200-day simple moving average ($0.35). Across its 52-week range of $0.22 to $0.58, MLSS sits at the 27.8% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.36).
Why MLSS Stock slipped -0.54% Today — RQD Quant Desk Flash. Stretched risk/reward at 5x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).